Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COALITION: Glofitamab with R-CHOP or Pola-RCHP in DLBCL
NCT04914741Phase 2Active, not recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glofitamab in diffuse large B-cell lymphoma (DLBCL) and high grade B-cell lymphoma (HGBCL) (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Number of participants with treatment-related adverse events at 60 months, Relative Dose Intensity of chemotherapy backbone at 12 months and 1 more. Started Jun 2021; status: active, not recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT04914741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914741.